Low-profile startup stakes its claim to Sanofi's siRNA platform in wake of setbacks
A biotech in China reports today that it will be scooping up a string of preclinical siRNA programs from Sanofi as the multinational player laterals a dormant development platform to the Lilly-backed group in Shanghai.
Details are sparse, but Rona Therapeutics — which scored a $33 million launch round in April from Lilly Asia Ventures, CMB International, Platanus, Fontus Capital and Lanting Capital — says it gained worldwide exclusive rights to Sanofi’s siRNA platform.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.